226 related articles for article (PubMed ID: 26802282)
21. Tobacco-specific N-nitrosamines and Areca-derived N-nitrosamines: chemistry, biochemistry, carcinogenicity, and relevance to humans.
Hoffmann D; Brunnemann KD; Prokopczyk B; Djordjevic MV
J Toxicol Environ Health; 1994 Jan; 41(1):1-52. PubMed ID: 8277523
[TBL] [Abstract][Full Text] [Related]
22. Chemical composition and carcinogenicity of smokeless tobacco.
Hoffmann D; Djordjevic MV
Adv Dent Res; 1997 Sep; 11(3):322-9. PubMed ID: 9524432
[TBL] [Abstract][Full Text] [Related]
23. Tobacco-specific nitrosamines in the saliva of Inuit snuff dippers in the Northwest Territories of Canada.
Brunnemann KD; Hornby AP; Stich HF
Cancer Lett; 1987 Oct; 37(1):7-16. PubMed ID: 3664451
[TBL] [Abstract][Full Text] [Related]
24. New brands of oral snuff.
Hoffmann D; Djordjevic MV; Brunnemann KD
Food Chem Toxicol; 1991 Jan; 29(1):65-8. PubMed ID: 1999307
[TBL] [Abstract][Full Text] [Related]
25. Unusually high levels of carcinogenic tobacco-specific nitrosamines in Sudan snuff (toombak).
Idris AM; Nair J; Ohshima H; Friesen M; Brouet I; Faustman EM; Bartsch H
Carcinogenesis; 1991 Jun; 12(6):1115-8. PubMed ID: 2044192
[TBL] [Abstract][Full Text] [Related]
26. Smokeless Tobacco Products (STPs) Harbour Bacterial Populations with Potential for Oral Carcinogenicity.
Monika S; Dineshkumar T; Priyadharini S; Niveditha T; Sk P; Rajkumar K
Asian Pac J Cancer Prev; 2020 Mar; 21(3):815-824. PubMed ID: 32212812
[TBL] [Abstract][Full Text] [Related]
27. An in Vitro Study of Constituents Released from Smokeless Tobacco Products into Human Saliva.
Guan S; Bush L; Ji H
J Anal Toxicol; 2022 Jul; 46(6):625-632. PubMed ID: 34155520
[TBL] [Abstract][Full Text] [Related]
28. N-Nitrosomorpholine and other volatile N-nitrosamines in snuff tobacco.
Brunnemann KD; Scott JC; Hoffmann D
Carcinogenesis; 1982; 3(6):693-6. PubMed ID: 6889471
[TBL] [Abstract][Full Text] [Related]
29. Tobacco-specific nitrosamines in new tobacco products.
Stepanov I; Jensen J; Hatsukami D; Hecht SS
Nicotine Tob Res; 2006 Apr; 8(2):309-13. PubMed ID: 16766423
[TBL] [Abstract][Full Text] [Related]
30. Chemical profile of two types of oral snuff tobacco.
Brunnemann KD; Qi J; Hoffmann D
Food Chem Toxicol; 2002 Nov; 40(11):1699-703. PubMed ID: 12176096
[TBL] [Abstract][Full Text] [Related]
31. Global surveillance of oral tobacco products: total nicotine, unionised nicotine and tobacco-specific N-nitrosamines.
Stanfill SB; Connolly GN; Zhang L; Jia LT; Henningfield JE; Richter P; Lawler TS; Ayo-Yusuf OA; Ashley DL; Watson CH
Tob Control; 2011 May; 20(3):e2. PubMed ID: 21109685
[TBL] [Abstract][Full Text] [Related]
32. Composition and Ecological Functionality of Fungal Communities Associated with Smokeless Tobacco Products Mainly Consumed in India.
Sajid M; Srivastava S; Yadav RK; Singh H; Singh S; Bharadwaj M
Microbiol Spectr; 2022 Aug; 10(4):e0227321. PubMed ID: 35695566
[TBL] [Abstract][Full Text] [Related]
33. The need for regulation of carcinogenic N-nitrosamines in oral snuff.
Djordjevic MV; Brunnemann KD; Hoffmann D
Food Chem Toxicol; 1993 Jul; 31(7):497-501. PubMed ID: 8340028
[TBL] [Abstract][Full Text] [Related]
34. In vitro permeation of nicotine and tobacco specific nitrosamines from smokeless tobacco product extracts in a 3D buccal tissue model.
Keyser BM; Flockton H; Weidman RA; Payne R; Rowe J; Jordan KG
Toxicol Lett; 2024 Feb; 392():36-45. PubMed ID: 38142871
[TBL] [Abstract][Full Text] [Related]
35. Free nicotine content and strategic marketing of moist snuff tobacco products in the United States: 2000-2006.
Alpert HR; Koh H; Connolly GN
Tob Control; 2008 Oct; 17(5):332-8. PubMed ID: 18669556
[TBL] [Abstract][Full Text] [Related]
36. From cultivation to cancer: formation of
Stanfill SB; Hecht SS; Joerger AC; González PJ; Maia LB; Rivas MG; Moura JJG; Gupta AK; Le Brun NE; Crack JC; Hainaut P; Sparacino-Watkins C; Tyx RE; Pillai SD; Zaatari GS; Henley SJ; Blount BC; Watson CH; Kaina B; Mehrotra R
Crit Rev Toxicol; 2023 Nov; 53(10):658-701. PubMed ID: 38050998
[TBL] [Abstract][Full Text] [Related]
37. Formulation of smokeless tobacco products with a wide range of pH to study nicotine pharmacokinetics and pharmacodynamics.
Hoag SW; Mishina EV; Viray L; Wang F; Hollenbeck G; Koszowski B; Pickworth WB
Pharm Dev Technol; 2022 Jul; 27(6):646-653. PubMed ID: 35850567
[TBL] [Abstract][Full Text] [Related]
38. Monitoring tobacco-specific N-nitrosamines and nicotine in novel Marlboro and Camel smokeless tobacco products: findings from Round 1 of the New Product Watch.
Stepanov I; Biener L; Knezevich A; Nyman AL; Bliss R; Jensen J; Hecht SS; Hatsukami DK
Nicotine Tob Res; 2012 Mar; 14(3):274-81. PubMed ID: 22039075
[TBL] [Abstract][Full Text] [Related]
39. Chemical analysis of Alaskan Iq'mik smokeless tobacco.
Hearn BA; Renner CC; Ding YS; Vaughan-Watson C; Stanfill SB; Zhang L; Polzin GM; Ashley DL; Watson CH
Nicotine Tob Res; 2013 Jul; 15(7):1283-8. PubMed ID: 23288872
[TBL] [Abstract][Full Text] [Related]
40. Variability of TSNA in U.S. Tobacco and Moist Smokeless Tobacco Products.
Oldham MJ; Lion KE; Phillips DJ; Morton MJ; Lusso MF; Harris EA; Jordan JL; Franke JE; Strickland JA
Toxicol Rep; 2020; 7():752-758. PubMed ID: 32612935
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
